title: Glioma-specific Domain IV EGFR cysteine mutations promote ligand-induced covalent receptor dimerization and display enhanced sensitivity to dacomitinib in vivo.
abstract: A feature of many gliomas is the amplification of the epidermal growth factor receptor (EGFR), resulting in its overexpression. Missense mutations or deletions within the extracellular domain are associated with this amplification and can lead to constitutive activation of the receptor, with the Domain I/II deletion, EGFRvIII, being the most common. These changes have also been associated with increased sensitivity to EGFR inhibition using small molecule inhibitors. We have expressed, in human glioma cells, EGFR containing four glioma-specific EGFR missense mutations within Domain IV (C620Y, C624F, C628Y and C636Y) to analyze their biological properties and sensitivity to EGFR inhibition. One of these mutants, C620Y, exhibited an enhanced basal phosphorylation, which was partially dependent on an EGFR-ligand autocrine loop. All Domain IV mutants responded equally as well as wildtype EGFR (wtEGFR) to ligand stimulation. Biochemical analysis revealed that a pre-formed, disulfide-bonded dimer associated with these mutations was underglycosylated, inactive and cytoplasmically retained. Ligand stimulation resulted in the formation of a tyrosine-phosphorylated, disulfide-bonded dimer for all Domain IV mutants but not for wtEGFR. Following treatment with the next-generation, irreversible pan-ErbB inhibitor dacomitinib, the C620Y, C624F and EGFRvIII mutants were inactivated, covalently dimerized and were retained in the cytoplasm, resulting in cell-surface receptor loss and, for C620Y and C624F, decreased binding of EGF. Dacomitinib treatment significantly reduced the in vivo growth of human glioma xenografts bearing C620Y, but not wtEGFR. Collectively, these data indicate that the unique biochemical traits of Domain IV EGFR cysteine mutants can be exploited for enhanced sensitivity to EGFR small molecule inhibitors, with potential clinical applications.
authors.affiliation: 160;CSIRO Division of Materials Science and Engineering, Parkville, VIC, Australia.
authors.forename: S A
authors.initials: SA
authors.lastname: Greenall
authors.affiliation: Oncogenic Signaling Laboratory and Brain Cancer Discovery Collaborative, Monash Institute of Medical Research, Clayton, VIC, Australia.
authors.forename: J F
authors.initials: JF
authors.lastname: Donoghue
authors.affiliation: Telethon Institute for Child Health Research and Brain Cancer Discovery Collaborative, Centre for Child Health Research, Subiaco, WA, Australia.
authors.forename: N G
authors.initials: NG
authors.lastname: Gottardo
authors.affiliation: Oncogenic Signaling Laboratory and Brain Cancer Discovery Collaborative, Monash Institute of Medical Research, Clayton, VIC, Australia.
authors.forename: T G
authors.initials: TG
authors.lastname: Johns
authors.affiliation: 160;CSIRO Division of Materials Science and Engineering, Parkville, VIC, Australia.
authors.forename: T E
authors.initials: TE
authors.lastname: Adams
mesh_terms: D000818:Animals; D045744:Cell Line, Tumor; D003545:Cysteine; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000235:genetics*; D005260:Female; D005910:Glioma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D006801:Humans; D008024:Ligands; D051379:Mice; D008807:Mice, Inbred BALB C; D009154:Mutation; D010766:Phosphorylation; D055503:Protein Multimerization; D017434:Protein Structure, Tertiary; D052999:Quinazolinones / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D008024:Ligands; D052999:Quinazolinones; C410723:epidermal growth factor receptor VIII; C525726:dacomitinib; C541485:EGFR protein, mouse; D066246:ErbB Receptors; D003545:Cysteine
references.citation: PLoS One. 2012;7(4):e34658
references.pmid: 22511956
references.citation: Nature. 1990 Dec 13;348(6302):647-9
references.pmid: 2174515
references.citation: Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2140-4
references.pmid: 1312714
references.citation: J Cell Sci. 2011 Sep 1;124(Pt 17):2938-50
references.pmid: 21878501
references.citation: Neoplasia. 2009 May;11(5):448-58, 2 p following 458
references.pmid: 19412429
references.citation: PLoS Med. 2006 Dec;3(12):e485
references.pmid: 17177598
references.citation: Neuropathol Appl Neurobiol. 2009 Apr;35(2):208-13
references.pmid: 19284481
references.citation: Growth Factors. 2009 Jun;27(3):141-54
references.pmid: 19333814
references.citation: Nat Rev Cancer. 2013 Sep;13(9):663-73
references.pmid: 23949426
references.citation: FASEB J. 2005 May;19(7):780-2
references.pmid: 15774576
references.citation: Science. 2007 Oct 12;318(5848):287-90
references.pmid: 17872411
references.citation: Mol Cell Biol. 2005 Sep;25(17):7734-42
references.pmid: 16107719
references.citation: Oncogene. 2014 Aug 14;33(33):4253-64
references.pmid: 24077285
references.citation: Cancers (Basel). 2011 Apr 18;3(2):2032-49
references.pmid: 24212795
references.citation: J Cell Physiol. 1997 Jul;172(1):117-25
references.pmid: 9207932
references.citation: Mol Cells. 2010 May;29(5):443-8
references.pmid: 20432069
references.citation: Biochim Biophys Acta. 2006 Aug;1763(8):870-8
references.pmid: 16842869
references.citation: Science. 2008 Sep 26;321(5897):1807-12
references.pmid: 18772396
references.citation: Int J Cancer. 2002 Mar 20;98(3):398-408
references.pmid: 11920591
references.citation: J Biol Chem. 1997 Sep 12;272(37):23247-54
references.pmid: 9287333
references.citation: Cancer Cell. 2013 Oct 14;24(4):438-49
references.pmid: 24135280
references.citation: Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4567-72
references.pmid: 9539778
references.citation: Nat Med. 2013 Nov;19(11):1389-400
references.pmid: 24202392
references.citation: Sci Rep. 2012;2:854
references.pmid: 23152945
references.citation: Cancer Cell. 2012 Oct 16;22(4):425-37
references.pmid: 23079654
references.citation: Nat Rev Cancer. 2007 Mar;7(3):169-81
references.pmid: 17318210
references.citation: Cancer Res. 2006 Jan 15;66(2):867-74
references.pmid: 16424019
references.citation: Mol Cell. 2003 Feb;11(2):507-17
references.pmid: 12620237
references.citation: J Biol Chem. 2007 Feb 2;282(5):2840-50
references.pmid: 17092939
references.citation: Cell. 2013 Oct 10;155(2):462-77
references.pmid: 24120142
references.citation: J Biol Chem. 1998 May 1;273(18):11150-7
references.pmid: 9556602
references.citation: FASEB J. 2010 Dec;24(12):4744-55
references.pmid: 20682838
references.citation: Oncogene. 2013 May 9;32(19):2403-11
references.pmid: 22751127
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Cancer Res. 2001 Aug 1;61(15):5790-5
references.pmid: 11479217
references.citation: Cell. 2013 Jan 31;152(3):557-69
references.pmid: 23374350
references.citation: Mol Biol Cell. 2002 Jul;13(7):2547-57
references.pmid: 12134089
references.citation: Science. 1995 Jan 20;267(5196):381-3
references.pmid: 7824936
references.citation: Cancer Res. 2000 Mar 1;60(5):1383-7
references.pmid: 10728703